Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The FRONTIER3 trial (NCT05306418) achieved its co-primary endpoints ...

Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER programme will be disclosed at upcoming congresses and in publications in 2025 and 2026.

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The company recently reported positive phase 3 results for Mim8 in patients with ...

Shareholders may receive a hard copy of Novo Nordisk’s completed audited financial ... results evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks ...

From Novo Nordisk's haemophilia portfolio, there are two oral presentations of note: first on the efficacy and safety results of an interim analysis from FRONTIER4, a phase 3 open-label, multi-centre ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025 – Novo ...